Company intelligence / Profile preview

Evotec SE

Ownership: Public · EVO
Employees: ~5000
Development stage: Phase 1

Overview

Evotec operates one of the largest partnered pipelines in the industry with over 130 active programs spanning discovery to clinical stages. Its business model focuses on co-developing assets with pharma partners using proprietary technology platforms. Clinical results are typically reported by partners rather than directly by Evotec.

Therapeutic areas: CardiovascularMetabolic DisordersRheumatologyNephrologyOncologyNeurology
Modalities: Small moleculesbiotherapeuticsbiologicsAI-driven drug discovery platforms
Industry: Biotech

Drug pipeline

18 assets

EVT-101

17 more assets in the full pipeline.

Request access →

Partnerships

Bristol Myers SquibbBayerSanofiBoehringer IngelheimCHDI FoundationEli Lilly & Co.Takeda Pharmaceutical Company Limited

Financials

Market cap: $646.5M
Total revenue: $145.9M
Enterprise value: $656.8M

Beyond the preview

Go deeper on Evotec SE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Evotec SE.

Explore the full profile